Trial Profile

A Phase 2, Multicenter, Open-label, Non-randomized, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of SAR445088 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jun 2024 According to Sanofi Media Release, data from the study were presented at the 2024 Peripheral Nerve Society (PNS) Annual Meeting in Montreal, Canada.
25 Jun 2024 Results presented in the Sanofi Media Release.
18 Apr 2024 Results presented at the 76th Annual Meeting of the American Academy of Neurology 2024, data for the SOC-Naive group will be presented at the AAN annual meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com